EIF2AK3 and osteogenesis imperfecta: Treatment with 4-PBA of fibroblasts from dominant OI patients with α1(I) mutations facilitated collagen folding and secretion, decreased the expression of eukaryotic translation initiation factor 2 alpha kinase 3 (PERK) and reduced the activation of apoptosis [67].